Phase III INVICTUS Trial Evaluates Ripretinib in Advanced GIST
Margaret von Mehren, MD, discusses the rationale for evaluating ripretinib in patients with heavily pretreated advanced GIST in the phase III INVICTUS trial, which was presented at the ESMO Congress 2019.
Margaret von Mehren, MD, from the Fox Chase Cancer Center, discusses the rationale for evaluating ripretinib (DCC-2618) in patients with heavily pretreated advanced gastrointestinal stromal tumors (GIST) inthe phase III INVICTUS trial, which was presented at the European Society for Medical Oncology (ESMO) Congress 2019.
The tumors in patients with GIST are driven by mutations primarily in 2 genes, which includeKITand PDGFRα. There are 3 drugs currently approved by the FDA for the treatment of these patients, including imatinib (Gleevec), sunitinib (Sutent), and regorafenib (Stivarga), von Mehren says. Following treatment with these therapies, many patients are clinically well and healthy enough to proceed with more therapy. However, there is a lack of therapies available following the 3 FDA-approved drugs.
TMLI Trial Shows Potential in Relapsed/Refractory Leukemia
October 2nd 2024In an interview, Jeffrey Wong, MD, and Anthony Stein, MD, provided an in-depth discussion on a phase 2 trial of total marrow and lymphoid irradiation with cyclophosphamide and etoposide in high-risk acute leukemia.
Read More
SABR and Hypofractionated Chemoradiation Improves Lung Cancer Outcomes
September 30th 2024Percy Lee, MD, discussed findings from a trial evaluating a hypofractionated approach to concurrent chemoradiation, incorporating an adaptive stereotactic ablative radiotherapy boost in non–small cell lung cancer.
Read More
